Sponsor Pipeline

iCell Gene Therapeutics Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
4
Recruiting
4
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-07-20 NCT07715136 BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy Phase 1 Recruiting
Active Trials by Phase
Phase 1/2
2
Phase 1
4
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT07328581 BCMA-CD19 cCAR T for the Treatment of Refractory Lupus Systemic Lupus Erythematosus (SLE) Not Yet Recruiting
NCT07544160 BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD) Inflammatory Bowel Diseases (IBD) Not Yet Recruiting
Phase 1
NCT06787989 BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with… Refractory Immune Cytopenia Recruiting
NCT04162353 BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma Multiple Myeloma in Relapse Recruiting
NCT07668557 Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute… Acute Myeloid Leukemia (AML) Recruiting
NCT07715136 BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy Inflammatory Myopathy Recruiting
Disease Areas
Get alerts when iCell Gene Therapeutics's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free